Henrique D. Teixeira
AbbVie (United States)(US)Universidade Federal dos Vales do Jequitinhonha e Mucuri(BR)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Asthma and respiratory diseases, Allergic Rhinitis and Sensitization, Urticaria and Related Conditions, Psoriasis: Treatment and Pathogenesis
Most-Cited Works
- → Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials(2021)515 cited
- → Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis(2021)459 cited
- → Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial(2021)374 cited
- → Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial(2019)348 cited
- → HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study(2015)191 cited
- → The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis